HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
-
ORGANIZATION EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
-
BUSINESS Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
October 25, 2018
-
BUSINESS AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
October 24, 2018
-
BUSINESS Parexel CEO Sees Bright Future for Japan CRO Market
October 23, 2018
-
BUSINESS Mundipharma Shooting for Japan Sales of US$500 Million in 10 Years: CEO
October 22, 2018
-
BUSINESS Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
-
REGULATORY 3 Pharma Groups Warn against Drug Price Cut in April 2019: Chuikyo
October 18, 2018
-
BUSINESS JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near
October 17, 2018
-
REGULATORY As Abe Vows to Deliver on Tax Hike Plan, 3 Pharma Groups to Push for October 2019 Price Revision
October 16, 2018
-
REGULATORY MEXT Kicks Off “Open Innovation Organization” Initiative, 3 Universities to Push Drug Discovery
October 15, 2018
-
BUSINESS Chugai Sues Daiichi Sankyo, Pfizer over Herceptin Biosimilars
October 15, 2018
-
TRENDS Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
-
BUSINESS Nippon Shinyaku to Expand Contract Manufacturing Biz with New Facility to Start Full Operation in Feb.
October 12, 2018
-
REGULATORY MHLW Panelists Frown on Use of Economic Evaluations for Reimbursement Decisions
October 11, 2018
-
REGULATORY MOF Reiterates Drug Cost Optimization, but Makes No Fresh Proposal: Fiscal System Council
October 10, 2018
-
BUSINESS Funding Disclosures Reveal Changes in Money Flows; Biz Models, Pricing Reform Driving the Shift
October 9, 2018
-
BUSINESS Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
-
BUSINESS Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
October 3, 2018
-
ACADEMIA I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
